TFO
SRPT icon

Tarbox Family Office’s Sarepta Therapeutics SRPT Stock Holding History

Tarbox Family Office’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12
Closed -$1K – 1203
2021
Q1 		$1K Buy
12
+3
+33% +$277 ﹤0.01% 1087
2020
Q4 		$2K Hold
9
– – ﹤0.01% 893
2020
Q3 		$1K Hold
9
– – ﹤0.01% 1059
2020
Q2 		$1K Sell
9
-7
-44% -$953 ﹤0.01% 1057
2020
Q1 		$2K Buy
16
+9
+129% +$1.03K ﹤0.01% 710
2019
Q4 		$1K Buy
+7
New +$707 ﹤0.01% 1055

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Tarbox Family Office's SRPT Position: Q2 2021 in Review

Tarbox Family Office sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 12 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in SRPT in Q4 2019 and held it in 6 quarters. The position peaked at $2K in Q4 2020. 330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

  • Tarbox Family Office reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Tarbox Family Office sold 12 Sarepta Therapeutics shares in Q2 2021, an estimated $1K.
  • Tarbox Family Office first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 6 quarters.
  • Tarbox Family Office's Sarepta Therapeutics position peaked at $2K in Q4 2020.
  • 330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Tarbox Family Office's 13F filing for Q2 2021, filed 16 Jul 2021.